Contrast-enhanced CBCT With C-arm HyperSight Technology (IV-CBCT)
2026年6月24日 更新者:University Health Network, Toronto
Contrast-enhanced CBCT With C-arm HyperSight Technology: A Feasibility Study
This is a single-arm prospective, feasibility study evaluating the intravenous contrast-enhanced cone beam computed tomography (IV CBCT) for image guidance during radiotherapy.
Patients treated with SFRT will receive IV-contrast enhanced CT and fMRI before treatment for simulation purposes.
Additionally, patients will receive mpMRI just before and IV-contrast enhanced CBCT during their second and last fraction of RT, in addition to the standard of care CBCT that is acquired for daily image-guided patient positioning.
Patients will undergo both IV-contrast enhanced CBCT and treatment on the TrueBeam with HyperSight imaging capability.
We hypothesize IV contrast enhanced CBCT is feasible, well-tolerated by patients and improves the visibility of the target.
研究概览
研究类型
介入性
注册 (估计的)
20
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Jelena Lukovic, MD FRCPC MPH MRMD
- 电话号码:4858 4169464501
- 邮箱:jelena.lukovic@uhn.ca
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 2M9
- 招聘中
- Princess Margaret Cancer Center
-
接触:
- Jelena Lukovic, MD FRCPC MPH MRMD
- 电话号码:4858 416-946-4501
- 邮箱:Jelena.Lukovic@uhn.ca
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Primary biopsy-proven cancer
- Planning to undergo spatially fractionated radiation therapy
- Able to provide informed consent
- Willingness to participate in follow-up
- ECOG less than or equal to 3
- Normal creatinine (below 109mmol/L), normal eGF
Exclusion Criteria:
- Unable to understand/provide consent
- History of allergic reaction to iodinated IV contrast dye (allergy to MR contrast is not an exclusion criteria)
- Known renal disease
- Single kidney
- Kidney transplant
- Dialysis
- Contraindication to MRI
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:IV CBCT
|
Two half-arc IV-contrast enhanced CBCT scans and mpMRI seuqences in addition to their routine standard of care CBCT that is done as part of image-guided radiotherapy.
These scans will be done during the second and last fraction of treatment.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Feasibility of IV-contrast enhanced CBCT during image-guided radiotherapy
大体时间:18 Months
|
Feasibility of IV-contrast enhanced CBCT in visualizing tumors, vascular structures and tumour micro-environment changes during image-guided radiotherapy.
The contrast-to-noise ratio, measuring the ability of an imaging modality to differentiate between various contrasts against the background noise, will be calculated and compared between CT and CBCT, and between with and without contrast acquisition.
|
18 Months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Feasibility of dynamic-contrast-enhanced (DCE) imaging
大体时间:18 Months
|
Assess tumor visualization and perfusion using the HyperSight C-arm system
|
18 Months
|
|
Image quality of full versus half (17 s) CBCT acquisition, with and without contrast enhancement
大体时间:18 Months
|
Noise-to-contrast evaluation of full and half CBCT acquisitions to ultimately assess sufficiency of scans for patient positioning and tumor visualization, and reduction of on-couch imaging time.
|
18 Months
|
|
Patient preferences and comfort with the use of IV CBCT during treatment
大体时间:18 Months
|
All patients will be asked to complete a patient experience survey to gauge their perceptions of receiving additional IV contrast during their CBCT.
All questions are answered on a 5-part Likert scale (strongly agree to strongly disagree) and grouped according to construct (knowledge, feelings and benefits).
Data will be analyzed using descriptive statistics.
Correlations will be examined between patient demographics (age, gender, ECOG performance status, ) and survey responses to identify any trends or specific needs.
|
18 Months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2026年6月24日
初级完成 (估计的)
2027年7月1日
研究完成 (估计的)
2027年7月1日
研究注册日期
首次提交
2026年6月9日
首先提交符合 QC 标准的
2026年6月9日
首次发布 (实际的)
2026年6月15日
研究记录更新
最后更新发布 (实际的)
2026年6月26日
上次提交的符合 QC 标准的更新
2026年6月24日
最后验证
2026年6月1日
更多信息
与本研究相关的术语
其他研究编号
- 24-5806
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.